Pay in 4 interest-free payments of $9.75 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
ciforadenant
terminal half-life (2
18(5):415-420
a minimum NU7026 exposure of 4 h in combination with 3 Gy radiation is required for a significant radiosensitisation effect in CH1 human ovarian cancer cells
4 μM for the inhibition of SK2
LDN-214117 - CAS# 1627503-67-6 60245 ciforadenantLDN 214117, CAS No. 1627503 67 6, is a selective and potent ALK2 inhibitor. LDN 214117 inhibited ALK2 most, with a biochemical IC50 of 24 nM. There are currently no effective therapies for fibrodysplasia ossificans progressiva (FOP), a debilitating and progressive heterotopic ossification disease caused by activating mutations of ACVR1 encoding the BMP type I receptor kinase ALK2. LDN 214117 shows a high degree of selectivity for ALK2 and low